The 3-Day Pill That Quiets the Hidden Fire in Your Arteries

Key Takeaway

An oral NLRP3 inflammasome inhibitor, ruvonoflast, cut hsCRP by 82.2% over 28 days in obese adults at high cardiovascular risk, separating from placebo by Day 3. It is a strong early sign that residual inflammatory risk might one day be treated with a pill. Whether it reduces heart attacks or strokes remains unproven.

The Patient Whose Statin Was Not Enough

She is 52, obese, and takes metformin, an ACE inhibitor and a high-intensity statin. Her LDL cholesterol finally sits at goal. Yet her high-sensitivity C-reactive protein reads 5.7 mg/L, more than double the threshold that signals residual inflammatory risk. She is a composite, but every internist knows her. For 2 decades we have lowered lipids with precision while the inflammation inside her arteries has gone largely untreated. The proven options are limited: an injectable antibody that few patients ever receive, and colchicine, which acts broadly rather than precisely. Now a small trial suggests that a twice-daily pill can begin to…